Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof

an angiogenesis and cephalotaxine technology, applied in the direction of biocide, drug composition, metabolic disorder, etc., can solve the problems of severe systemic toxicity at the dose required for antitumor activity, and achieve the effect of inhibiting unwanted angiogenesis and inhibiting angiogenesis

Inactive Publication Date: 2009-10-29
CHEMGENEX PHARMA
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011]In accordance with the objects outlined above, the present invention provides compositions and methods that are effective in inhibiting unwanted angiogenesis. One aspect of the invention provides for a method of treatment of a host with an angiogenic disease, comprising contacting the host with a cephalotaxine in amount sufficient to inhibit angiogene

Problems solved by technology

Several angiogenesis inhibitors are currently under development for use in treating angiogenic diseases (Gasparini, G. and Harris, A. L., (1995) J. Clin. Oncol., 13(3): 765-782), but there are disadvantages associated with these compounds.
Suramin, for example, is a potent angiogenesis inhibitor but causes severe systemic toxicity at the doses required for antitumor activity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
  • Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
  • Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effects of Homoharringtonine in the CAM Assay

Protocol:

[0063]Fertilized chicken eggs (HiChick Breeding Co, Kapunda, South Australia) were incubated for three days at 38° C. On Day 3 the embryos were cracked out of the egg and into a cup made of plastic piping, with plastic film stretched over the top to form a hammock for the egg to be suspended in. Two ml of DMEM containing penicillin and streptomycin was added to each cup prior to the egg being added. A Petri dish on the top maintained sterility. Incubation continued in a humidified 37° C. incubator.

[0064]On Day 4 the chorioallantoic membrane (CAM) begins to grow, and pictures were taken of each embryo at ×5 to measure the CAM area using image analysis software (Video Pro 32, Leading Edge Pty Ltd, South Australia). Embryos were then grouped according to their CAM area, with a control embryo in each for comparison. There were four matched embryos, treated with 6.25, 12.5 and 25 ng of homoharringtonine. Grouping is critical as in the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Angleaaaaaaaaaa
Angleaaaaaaaaaa
Disorderaaaaaaaaaa
Login to View More

Abstract

The invention relates to compositions and methods useful in treating or preventing angiogenic disease. The invention provides for compositions comprising cephalotaxine alkaloids as antiangiogenic agents for treatment of a host with an angiogenic disease or for prophylactic treatment of a host to inhibit the onset or progression of an angiogenic disease.

Description

[0001]This application is a continuation of U.S. application Ser. No. 10 / 625,866, filed Jul. 22, 2003, now pending, which claims under 35 USC 119(e) the benefit of U.S. Application 60 / 397,657, filed Jul. 22, 2002, each of which is incorporated by reference in its entirety for all purposes.TECHNICAL FIELD[0002]The invention relates to compositions and methods useful in treating or preventing angiogenic disease. The invention provides for compositions comprising cephalotaxine alkaloids as antiangiogenic agents for treatment of a host with an angiogenic disease or for prophylactic treatment of a host to inhibit the onset or progression of an angiogenic disease.BACKGROUND OF THE INVENTION[0003]Angiogenesis is defined as the formation and differentiation of new blood vessels. It has been linked to a number of diseases and conditions, in particular to cancer, inflammation and certain retinal disorders. Angiogenic diseases include, but are not limited to, solid tumors, diabetic retinopathy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/55A61P35/00A61P29/00A61P27/00C07D491/147A61P11/00A61P11/06A61P19/02A61P27/02A61P35/04
CPCA61K31/55A61P3/10A61P11/00A61P11/06A61P19/02A61P27/00A61P27/02A61P27/06A61P27/12A61P29/00A61P35/00A61P35/04Y02A50/30
Inventor BROWN, DENNIS M.
Owner CHEMGENEX PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com